Scribe Reports Narrower Loss In Q2 Due To Lower Expenses
(RTTNews) - Scribe Therapeutics Inc. (SCTX) reported on Wednesday second quarter financial results, highlighting narrower net loss, due to lower expenses and a gain in the fair value of convertible notes. The company also provided corporate highlights and detailed upcoming milestones.
Company Profile
Scribe Therapeutics is a clinical-stage biotechnology company, focused on developing in vivo CRISPR-based genetic medicines for cardiovascular and metabolic diseases.
FY26 Second Quarter Highlights
Net loss for the quarter narrowed to $6.48 million, or $2.62 per share, from $9.90 million, or $4.08 per share, in the prior-year quarter.
The narrower quarterly loss is attributed to reduced operating expenses of $11.31 million, while in the previous year expenses were $16.52 million.
The company also gained $3.02 million from a change in fair value of convertible notes from 0.73 million in a year-ago quarter.
Cash, cash equivalents and investments totalled $43.01 million as of June 30, 2026.
Corporate Highlights
The company began trading on the Nasdaq market on July 24, 2026, and raised gross proceeds of $155.5 million in the initial public offering. The company expects the current cash runway, gross proceeds from the IPO and a concurrent private placement to fund its operating expenses and capital expenditure requirements into the first half of 2029.
Clinical Highlights & Upcoming Milestones
STX-1150: In vivo epigenetic silencing therapy for LDL-C lowering
Scribe initiated a Phase 1 trial of STX-1150 in Australia in mid-2026. The investigational, liver-targeted CRISPR-based therapy is designed to repress the PCSK9 gene and lower LDL-C without permanently altering DNA. In a preclinical study, the drug showed to reduce up to 68% of LDL-C following a single dose, with reductions of more than 50% sustained for two years.
The company expects to report initial clinical data for the Phase 1 trial in the first half of 2027.
STX-1200 and STX-1400: Advancing cardiometabolic gene editing programs targeting genetically driven, severely elevated Lp(a) and triglycerides
Scribe received approximately $25.7 million in combined CIRM grants to advance STX-1200 and STX-1400 toward clinical development. STX-1200 targets the LPA gene to lower lipopolysaccharide a (Lp(a)), while STX-1400 targets APOC3 gene to lower triglycerides. Both programs are targeted for clinical entry as early as 2027.
SCTX closed at $30.90, up 6.55%.
